Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of Cassava Sciences' next Alzheimer's drug trial?
Successful with measurable cognitive improvement • 25%
Partially successful with some cognitive improvement • 25%
Unsuccessful with no cognitive improvement • 25%
Trial canceled or postponed • 25%
Official trial results published by Cassava Sciences
Cassava Sciences, Founder, and CUNY Scientist Settle SEC Charges Over Alzheimer's Data Manipulation
Sep 26, 2024, 10:53 PM
Cassava Sciences Inc. (NASDAQ: SAVA) and two former executives have settled with the Securities and Exchange Commission (SEC) for $40 million over charges of misleading claims regarding their Alzheimer's clinical trial. The SEC alleges that the company falsified data from their Phase 2b trial, which showed no measurable cognitive improvement in patients' episodic memory. Key figures involved include founder Remi Barbier, his wife Lindsay Burns, and Dr. Wang of the City University of New York (CUNY), who were charged with manipulating research results. Despite these allegations, Cassava Sciences maintains a market valuation of $1.5 billion, and its stock performance remains strong over the past one, two, and five years.
View original story
Results lead to renewed interest • 25%
Results confirm initial failure • 25%
Mixed reception from the scientific community • 25%
No significant impact • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Favorable ruling for Cassava Sciences • 25%
Unfavorable ruling for Cassava Sciences • 25%
Settlement • 25%
Case dismissed • 25%
New Alzheimer's drug candidate announced • 25%
Focus shifts to different therapeutic area • 25%
Company gets acquired • 25%
Continues current operations without major changes • 25%
Announce a new drug development • 25%
Seek partnerships or mergers • 25%
Focus on non-Alzheimer's projects • 25%
Other strategic move • 25%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Cassava Sciences wins the lawsuits • 25%
Cassava Sciences settles the lawsuits • 25%
Cassava Sciences loses the lawsuits • 25%
Lawsuits are dismissed • 25%
Profitable • 25%
Break-even • 25%
Loss-making but stable • 25%
Facing financial distress • 25%
Revenue increases by 10% or more • 25%
Revenue stays within 10% of current levels • 25%
Revenue decreases by 10% or more • 25%
Cassava Sciences reports a loss • 25%
Below $20 • 25%
Above $60 • 25%
$40 to $60 • 25%
$20 to $40 • 25%